Previous work from this laboratory has shown that the electrically evoked release of enkephalin from the guinea pig myenteric plexus is regulated by an opiate receptor-mediated, concentration-dependent mechanism. Low concentrations (nanomolar) of opioids enhance release, whereas higher concentrations (10-100 nM) inhibit release. Each opioid effect is mediated by a different guanine nucleotide-binding protein. We now demonstrate that activation of cholinergic receptors in the myenteric plexus is a prerequisite for opioid excitatory effects, but not inhibitory effects, on enkephalin release. Pretreatment with the muscarinic cholinergic receptor antagonist atropine abolishes the opioid facilitation of stimulated enkephalin release but does not alter the inhibition of release that is observed with higher concentrations of opioid agonist. Exposure to the calcium ionophore A23187 overcomes the abolishment of opioid enhancement of enkephalin release produced by cholinergic receptor blockade. In tissue treated with both atropine and A23187, the magnitude of the opioid enhancement of release is indistinguishable from that observed in untreated preparations. This suggests that the lack of stimulation-induced generation of elevated cytosolic calcium is responsible for the abolishment of faciitory opioid effects when cholinergic receptors are blocked. The known coupling of muscarinic receptors to phospholipase C activation and the generation of inositol trisphosphate (which elevates cytosolic calcium) could suggest that this second messenger is critical for the manifestation of opioid facilitation of enkephalin release.
Each opioid effect is mediated by a different guanine nucleotide-binding protein. We now demonstrate that activation of cholinergic receptors in the myenteric plexus is a prerequisite for opioid excitatory effects, but not inhibitory effects, on enkephalin release. Pretreatment with the muscarinic cholinergic receptor antagonist atropine abolishes the opioid facilitation of stimulated enkephalin release but does not alter the inhibition of release that is observed with higher concentrations of opioid agonist. Exposure to the calcium ionophore A23187 overcomes the abolishment of opioid enhancement of enkephalin release produced by cholinergic receptor blockade. In tissue treated with both atropine and A23187, the magnitude of the opioid enhancement of release is indistinguishable from that observed in untreated preparations. This suggests that the lack of stimulation-induced generation of elevated cytosolic calcium is responsible for the abolishment of faciitory opioid effects when cholinergic receptors are blocked. The known coupling of muscarinic receptors to phospholipase C activation and the generation of inositol trisphosphate (which elevates cytosolic calcium) could suggest that this second messenger is critical for the manifestation of opioid facilitation of enkephalin release.
Previous work from this laboratory has shown that the electrically evoked release of [Met5] enkephalin from the myenteric plexus can be modulated by ,, 8 , and K types of opiate receptor. This modulation is bimodal. Low concentrations (nanomolar) enhance the magnitude of stimulated release, whereas higher concentrations (10- MATERIALS AND METHODS "Strips" of the guinea pig LMMP were prepared, mounted, and superfused in a stimulating chamber as described (3, 5, 6) . The Krebs solution used to superfuse (pass over) the tissue contained 10 mM captopril, 0.3 mM thiorphan, 10 mM bestatin, and 2 mM L-leucyl-L-leucine to protect against the action of proteases (7). The superfusion rate was maintained at 1 ml/min. Fractions (0.5 ml) were collected on ice and oxidized immediately with 0.3% hydrogen peroxide at 4°C overnight, after which duplicate 100-,ul aliquots of each sample were Iyophilized to dryness. The protease inhibitors mentioned above were present during the 30-min equilibration period before the start of each experiment and thereafter for its duration. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 1979 benzeneacetamide (U50,488H; Upjohn) were utilized as it-, 8-, and K-selective opiate receptor agonists, respectively (8, 9) . Enkephalin-like immunoreactivity was determined by using an RIA procedure as described (1) [Leu5]enkephalin, a-endorphin, f3-endorphin, and y-endorphin was less than 0.1% (10) . High-pressure liquid chromatography fractionation in combination with RIA indicated that >90% of enkephalin-like immunoreactivity was authentic [Met5]enkephalin (6) . In experiments involving A23187, the calcium ionophore was added to the LMMP superfusate 5 min before the application of electrical stimulation in each cycle of release.
The opioid responsiveness of untreated preparations and preparations treated with cholinergic receptor antagonists was analyzed by using a three-way analysis of variance. Experiments involving the effect of atropine on excitatory opioid responsiveness in forskolin-or naloxone-treated preparations was analyzed by using a one-way analysis of variance. Planned comparisons were tested by using Student's t test; P > 0.05 is considered insignificant. The effect of A23187 on excitatory opioid responsiveness in atropinetreated and untreated preparations was analyzed by using Student's t test. To avoid the potential confound of performing multiple t tests, P > 0.01 is considered insignificant (Bonferroni method). (10 ,uM Pretreatment with hexamethonium also prevented the forskolin reversal of [D-Pen2 5]enkephalin-induced inhibition to enhancement but had no effect on the ability of forskolin to reverse the inhibition of [Met5]enkephalin release produced by SFNC. These results parallel the effect of nicotinic receptor blockade on the enhancement of release produced by these compounds in the absence of forskolin (see Fig. 1 Stimulation of muscarinic cholinergic receptors is often associated with the activation of the enzyme phospholipase C (11) (12) (13) . This results in the intracellular generation of the phosphatidylinositol-derived second-messenger inositol trisphosphate (InsP3) (14, 15) , which causes the release of calcium from the endoplasmic reticulum, increasing its concentration in the cytosol (16) (17) (18) . To assess the possible involvement of InsP3 (and intracellular calcium) in the opioid excitatory response, the effect of the calcium ionophore A23187 on the atropine blockade of opioid enhancement of [Met5]enkephalin release was determined (see Fig. 5 ). In these experiments, the LMMP preparation was exposed to 1 A.M A23187 for 5 min prior to stimulation in each cycle and maintained for its duration. Treatment with atropine and the quantitation of the magnitude of opioid enhancement of release was as described above.
RESULTS
Pretreatment of the LMMP preparation with A23187 significantly altered the ability of atropine to block the opioid enhancement of [Met5]enkephalin release (P < 0.002 for SFNC, [D-Pen2'5]enkephalin, or U50,488H in the presence vs. the absence of A23187 in atropine-treated preparations). In tissue treated with A23187, opioid enhancement of release was manifest despite the blockade of muscarinic receptors (Fig. 5) . Furthermore, in LMMP preparations treated with both atropine and A23187, the magnitude of the opioid enhancement of [Met5]enkephalin release was indistinguishable from that observed in untreated tissue (P = 0.09, 0.20, (11) (12) (13) (14) (15) . This results in the generation of InsP3, which causes an increase in cytosolic calcium levels (14) (15) (16) (17) (18) . It is tempting to speculate that this cholinergic receptor-coupled event may be critical for the manifestation of opioid excitatory effects.
InsP3 is highly charged and does not penetrate the cell membrane. Consequently, the exogenous application of InsP3 cannot be used to stimulate its intracellular receptor and release calcium from the endoplasmic reticulum. However, this consequence of activating InsP3 receptors can be simulated by the extracellular application of a calcium ionophore such as A23187.
Treatment with A23187 overcomes the abolishment of opioid enhancement of [Met5]enkephalin release that is produced by blockade of muscarinic receptors. However, identical treatment in the absence of atropine does not enhance excitatory opioid responsiveness. This suggests that the lack of stimulation-induced generation of increased cytosolic calcium (presumably resulting from the formation of InsP3) is responsible for the abolishment of facilitory opioid effects when cholinergic receptors are blocked. The involvement of phosphotidylinositol-derived second messengers in the opioid facilitation of [Met5]enkephalin release would be consistent with a previous finding in bovine adrenal chromaffin cells. In this preparation, muscarinic receptor stimulation does not by itself evoke the release of epinephrine but nevertheless enhances nicotine-induced catecholamine secretion, an effect that is paralleled (and presumably mediated) by the rapid accumulation of InsP3 (19) .
In summary, cholinergic activity (muscarinicreceptor activation) is a prerequisite for opioid enhancement, but not inhibition, of stimulated [Met5Jenkephalin release. The ability of A23187 to reverse the atropine blockade of the opioid enhancement ofrelease combined with the known coupling of muscarinic receptors to phospholipase C activation and the generation of InsP3 could suggest that this second messenger is critical for the manifestation of opioid facilitation of
[Met5]enkephalin release. The divergence of the biochemical mechanism(s) that mediates opioid facilitation or inhibition indicates that in vivo each effect can be differentially and independently regulated. The pharmacological manipulation of relative responsiveness to opioid excitation or inhibition might increase the effective use of narcotics to manage pain.
